Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours (NCT02582697)
Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours.
Who can join: Review the eligibility criteria below.
Location: Memorial Sloan Kettering Cancer Centre — New York, New York
Age range: 11 Years to 50 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (28 Sites)
Showing the first 25 of 28 sites.
- Memorial Sloan Kettering Cancer Centre — New York, New York
- Calvary Mater Newcastle — Newcastle, New South Wales
- Royal North Shore Hospital — St Leonards, New South Wales
- Prince of Wales Hospital — Sydney, New South Wales
- Chris O'Brien Lifehouse — Sydney, New South Wales
- Macquarie Cancer Clinical Trials — Sydney, New South Wales
- Concord Repatriation General Hospital — Sydney, New South Wales
- Westmead Hospital — Sydney, New South Wales
- Nepean Hospital — Sydney, New South Wales
- Tweed Hospital — Tweed Heads, New South Wales
- SAN Clinical Trials Unit — Wahroonga, New South Wales
- Royal Brisbane & Women's Hospital — Brisbane, Queensland
- Queensland Children's Hospital — South Brisbane, Queensland
- Princess Alexandra — Woolloongabba, Queensland
- Royal Adelaide Hospital — Adelaide, South Australia
- Flinders Medical Centre — Bedford Park, South Australia
- Royal Hobart Hospital — Hobart, Tasmania
- Box Hill Hospital — Box Hill, Victoria
- Peter MacCallum Cancer Centre — East Melbourne, Victoria
- Austin Health — Heidelberg, Victoria
- Sunshine Hospital — St Albans, Victoria
- Border Medical Oncology — Wodonga, Victoria
- Fiona Stanley Hospital — Murdoch, Western Australia
- Starship Children's Hospital — Grafton, Auckland
- Auckland Hospital — Grafton, Auckland
📞 Contact the Study Coordinator
Phone: (619) 562-5000
Email: p3bep@ctc.usyd.edu.au
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Germ Cell Tumor
- Proton Beam Radiation Therapy for Central Nervous System (CNS) Germ Cell Tumors — Boston, Massachusetts
- Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors — Basking Ridge, New Jersey
- A Study of miRNA 371 in Patients With Germ Cell Tumors — Gilbert, Arizona
- Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors — Birmingham, Alabama
- A Phase II Trial of Cabozantinib With Patients With Refractory GCTs — Indianapolis, Indiana
Explore by condition: All Germ Cell Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.